Placenta-derived mesenchymal stem cells (MSCs) are multipotent stem cells with a high capacity for self-renewal. Placenta mesenchymal stem cells can develop into specialized cells of the body such as chondrocytes, osteoblasts, and adipocytes, and their easy accessibility, exceptional genomic stability, and capacity for tissue repair with few immunological and ethical issues make them a favorable cell type for experimental and clinical use. Importantly, MSCs derived from neonatal tissues have shown greater proliferative capacity and lower immunogenicity than adult bone marrow-derived MSCs. Human chorionic plate-derived mesenchymal stem cells (hCP-MSCs; isolated from the fetal portion of the placenta) have been shown to exhibit better adipogenesis efficiency, greater clonogenic potential, and higher expression of genes related to cell cycle progression and genome stability than other placental tissues, and so are ideal for different experimental or clinical applications.
Human placental mesenchymal stem cells were isolated from the chorionic plate of the placenta (female offspring). The human placental cells are cultured, passaged for purity, cryopreserved, and delivered frozen. Each vial contains 1 x 106 cells in 1 mL volume. Human placental MSC are characterized by flow cytometry for CD90, CD105, CD73, CD45, and CD34. hCP-MSCs are negative for mycoplasma, yeast, fungi, and bacteria. HIV-1, HIV-2, and HBV are not detected. Cells are assured to further culture using the protocol provided by JangoCell.
Human chorionic plate-derived mesenchymal stem cells (hCP-MSCs) are also known as: CP-MSCs, P-MSCs, pMSCs, chorionic MSCs, human chorionic-plate-derived MSCs, placenta tissue-derived MSCs, human placenta cells, human placental stem cells, stem cells from placenta, and placenta stem cells.
This cell product is intended for laboratory research purposes only. Not approved for use in human subjects or for clinical, diagnostic, or therapeutic use in animals or humans.
Human Material Precaution
Tissues used for cell isolation were acquired with informed consent and adhere to HIPAA standards for human privacy protection. All human biological material, including human cells, should always be handled as potentially infectious using at least Biosafety Level 2 precautions; we recommend that appropriate safety procedures be followed, using the same biosafety protocol used with known infectious material. Viral testing cannot prove the absence of a latent viral genome.